

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	U.S. National Phase of PCT Application No.
--------------------	--

Application Number:	PCT/BE2004/000172
Filing Date:	2004.03.03

Filing Date	A	December 2, 200
-------------	---	-----------------

First Named Inventor	Dr. [illegible]
----------------------	-----------------

Art Unit

Examiner Name _____

Attorney Docket Number	29248/29
------------------------	----------

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	8	DE 40 39 631 A	06-17-1992	Troponwerke GmbH & Co. KG		
	9	WO 98/11897 A	03-26-1998	Eli Lilly and Company		
	10	WO 98/43646 A	10-08-1998	Akzo Novel N.V.		
	11	WO 00/64441 A	11-02-2000	Respiratorius AB		
	12	WO 01/98298 A	12-27-2001	H. Lundbeck A/S		
	13	WO 02/051833 A	07-04-2002	H. Lundbeck A/S		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

1AP20 Rec'd PCT/PTO 31 MAY 2006

PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	U.S. National Phase of PCT Application No. PCT/BE2004/000172A 1500962
				Filing Date I.A.	December 21, 2004 1500962
				First Named Inventor	Erik Buntinx
				Art Unit	
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	29248/29

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	14	SCHINDLER T., et al., "Palliative medical management in anxiety and depression." Zeischrift Fur Allgemeinmedizin, vol. 74, No. 21, November 5, 1998, pp. 973-978.	
	15	VOLMAT R., et al., "The treatment of depressions by Cledial. Evolution and clinical state and handwriting." Psychologie Medicale, vol. 18 (10), 1986, pp. 1615-1622.	
	16	FOUKS, et al., "Treatment of character disorders with a new butyrophenone: R. 3345 or pipamperone." Annales Medico-Psychologiques, vol. 124, No. 5, 1966, pp. 677-681.	
	17	SQUELART P, et al., "Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients." Acta Psychiatrica Belgica, vol. 77, No. 2, March 1977, pp. 284-293.	
	18	KOCH HJ, et al., "Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapinr and tiapride." International Journal of Clinical Practice, vol. 57, No 2, March 2003, pp. 147-149.	
	19	DIEBOLD K, et al., "Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?" Pharmacopsychiatry, 1998, Vol 31, pp.60-67.	
	20	GROZINGER M, et al., "Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine." Pharmacopsychiatry, vol. 36, No. 1, January 2003, pp. 3-6.	
	21	PERUGI G, et al., "Effectiveness of adjunctive gabapentin in resistant bipolar disorder: Is it due to anxious-alcohol abuse comorbidity?" Journal of Clinical Psychopharmacology, vol. 22, No. 6, 2002, pp. 584-591.	
	22	WIELING, W et al., "Initial orthostatic hypotension as a cause of recurrent syncope: A case report." Clinical Autonomic Research, vol. 11 (4), 2001, pp. 269-270.	
	23	DATABASE PHARMAPROJECTS ONLINE! PJB Publications Ltd., December 1999. Caesar Accession No. 1498 (2 pages).	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	U.S. National Phase of PCT Application No. PCT/BE2004/009172
				Filing Date I.A.	December 2, 2004 11/2004 962
				First Named Inventor	Erik Buntinx
				Art Unit	
				Examiner Name	
Sheet	3	of	5	Attorney Docket Number	29248/29

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	24	ADLER L, et al., "Praxis Der Stationaeren Akutbenhandlung Von Manien Restrospektive Vergleichsuntersuchung An Je 100 Patienten Zweier Psychiatrischer Zentren. Practice of In-Patient Acute Treatment of Manias." Fortschritte Der Neurologie Psychiatrie, Stuttgart, vol. 62, No. 12, 1994, pp. 479-488.	
	25	ANSOMS C, et al., "Sleep disorders in patents with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamperone (Dipiperone)." Acta Psychiatrica Scandinavica, vol. 55, No. 2, February 1977, pp. 116-122.	
	26	LEYSEN JE, et al., "Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects." International Journal of Psychiatry in Clinical Practice, vol. 2, No. 1, 1998, pp. S3-S17.	
	27	VANHOENACKER P, et al., "Efficient expression of the human dopamine D4.2 receptor: Positive influence of pipamperone on expression levels." Abstracts of the Society for Neuroscience, vol. 26 No.1/2, 2000.	
	28	SCHOTTE A, et al., "Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding." Psychopharmacology, vol. 124, No. 1-2, 1996, pp. 57-73.	
	29	WOGGON B, "Pharmakologische depressionbehandlung. Pharmacological treatment of depression." Therapeutische Umschau, vol. 57, No. 2, 2000, pp. 81-89.	
	30	VAN DE VIJVER DAMC, et al., "Antipsychotic and Parkinson's disease: Association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment." Eur. J. Clin. Pharmacology, vol. 58, 2002, pp. 157-161.	
	31	JOVIC NI, et al., "Phenomenology and treatment of delirium in Alzheimer's disease" Revue Medicale De La Suisse Romande, vol. 117, No. 9, September 1997, pp. 655-658.	
	32	ENGELBORGH S, et al., "Amino acids of biogenic amines in cerebrospinal fluid of patients with Parkinson's disease." Neurochemical Research, vol. 28 No. 8, August 2003, pp. 1145-1150.	
	33	NEWMAN-TANCREDI A, et al., "[35S]-guanosine-5'-O-(3-thio) triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: Actions of antiparkinsonian and antipsychotic agents." Journal of Pharmacology and Experimental Therapeutics, vol. 282 (1), 1997, pp. 181-191.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	U.S. National Phase of PCT Application No. PCT/BE2004/000172
				Filing Date I.A.	December 2, 2004 33/580962
				First Named Inventor	Erik Buntinx
				Art Unit	
				Examiner Name	
Sheet	4	of	5	Attorney Docket Number	29248/29

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	34	TARZI FI, et al., "Role of dopamine D4 receptors in neuropsychiatric disorders." Journal of Neurochemistry, vol. 81, supp. 1, June 2002, p. 33, Abstract.	
	35	TARZI FI, et al., "Dopamine D4 receptors: Significance for molecular psychiatry at the millennium." Molecular Psychiatry, vol. 4, No 6, November 1999, pp. 529-538.	
	36	LEOPOLD NA, "Risperidone treatment of drug-related psychosis in patients with parkinsonism." Movement Disorders, vol. 15, No 2, March 2000, pp. 301-304.	
	37	TAHAR AH, et al., "Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys." European Journal of Pharmacology, vol. 399, No 2-3, July 7, 2000, pp. 183-186.	
	38	ZESIEWICZ TA, et al., "Clozapine withdrawal symptoms in a Parkinson's disease patient." Movement Disorders, vol. 17, No 6, November 2002, pp. 1365-1367.	
	39	FALTRACO F, et al., "Aktuelle therapeiemoglichkeiten der alzheimer demenz (current therapeutical strategies in dementia)." Neurol. Rehabil. 2003, 9(1), pp. 15-22.	
	40	ETCHEPAREBORDA MC, "Neurocognitive and pharmacological approach to specific learning disorders." Database Medline Online, US National Library of Medicine, February 1999, and Revista De Neurologia, vol. 28, suppl. 2, February 1999, pp. S81-S93, Abstract.	
	41	STAHL SM, et al., "Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease." Current Medical Research and Opinion 2004, vol. 20, No 4, pp. 517-524.	
	42	MENESES, A, "Are 5-HT 1B/1D and 5-HT 2A/2B/2C receptors involved in learning and memory processes?" Drugs 1999, vol. 2 (8), 1999, pp. 796-801.	
	43	WIRZ-JUSTICE A, et al., "Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease." Alzheimer Disease and Associated Disorders, vol. 14, No 4, 2000, pp. 212-215.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	U.S. National Phase of PCT Application No. PCT/BE2004/009173
				Filing Date I.A.	December 2, 2004 10/580962
				First Named Inventor	Erik Buntinx
				Art Unit	
				Examiner Name	
Sheet	5	of	5	Attorney Docket Number	29248/29

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	44	FAHS H, et al., "Thymoregulateurs Dans L'Agitation et les Troubles Du Comportement Chez le Sujet Dement a Propos de Huit Cas, Anticonvulsivants and Aggressive Behaviors in Alzheimer's Disease. Eight Cases Reports." L'Encephale, vol. 25, No 2, 1999, pp. 169-174.	
	45	WERTH E, et al., "Decline in long-term circadian rest-activity cycle organization in a patient with dementia." Journal of Geriatric Psychiatry and Neurology, vol. 15, No 1, April 2002, pp. 55-59.	
	46	MELTZER HY, et al., "Plasma clozapine levels and the treatment of L-Dopa-induced psychosis in Parkinson's disease. A high potency effect of clozapine." Neuropsychopharmacology, vol. 12, No 1, 1995, pp. 39-45.	
	47	MUNCHAU A, et al., "Pharmacological treatment of Parkinson's disease." Postgraduate Medical Journal, vol. 76, October 2000, pp. 602-610.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.